{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045984","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.444405+00:00","generated_at":"2026-05-30T03:26:15.350626+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Esperion Q3 revenue $51.6M (+52% YoY); net loss narrows to $29.5M","bullets":["Total revenue $51.6M (+52% YoY); U.S. net product revenue $31.1M (+53% YoY).","Net loss $29.5M (EPS -$0.15) vs. $41.3M loss (-$0.37) in Q3 2023.","Cash & equivalents $144.7M at Sep 30, up from $82.2M at Dec 31, 2023.","Retail prescription equivalents +12% QoQ; Oct 2024 TRx +17% vs. first 4 weeks of Q3.","European partner DSE royalty revenue $8.9M (+19% sequentially); Otsuka on track for Japan NDA filing by end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045984","json":"https://secwatch.observer/filing/0001628280-24-045984.json","markdown":"https://secwatch.observer/filing/0001628280-24-045984.md","text":"https://secwatch.observer/filing/0001628280-24-045984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024045984/0001628280-24-045984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024045984/espr-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:26:15.350626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}